Important: Consult & MD approval required
Rather, they facilitate a pinched, unromantic, grindingly efficient form of productivity
Following the positive REDEFINE 1 Phase 3 data (published June 2025, PMID: 40544433), Novo Nordisk announced plans to file regulatory applications for CagriSema for obesity in the United States (FDA), European Union (EMA), and other major markets in 20252026
It acts as a dual agonist at amylin receptors (AMY1R, AMY2R, AMY3R, formed by calcitonin receptor heterodimerized with RAMP1-3) and calcitonin receptors, with structural modifications (e.g., N-terminal fatty acid acylation, proline substitutions) preventing fibril formation, enhancing stability, and enabling once-weekly dosing via albumin binding for prolonged circulation
Research design questions about combining compounds across mechanisms are outside the scope of supplier guidance